Sybil Lung Cancer Consortium
Learn more
Our Mission
The Sybil Lung Cancer Consortium is an alliance of leading scientists and clinicians taking a proactive approach through the development and deployment of state-of-the-art AI tools like Sybil that can help detect lung cancer earlier. We aim to change screening policies to accommodate AI tools that could transform our understanding of lung health.
Read moreOur Principal Investigators
Regina Barzilay
AI Faculty Lead
William Mayfield
Chief Surgical Officer, WellStar Health System
Raymond Osarogiagbon
Chief Scientist, Baptist Memorial Health Care
Mary Pasquinelli
Director, Lung Screening Program, UI Chicago
Lecia Sequist
Landry Family Professor of Medicine, Harvard Medical School
About
Lung cancer is the world’s deadliest cancer, claiming more lives than any other cancer. The Sybil Lung Cancer Consortium is a collaborative of 37 researchers across five institutions studying the deployment of state-of-the-art AI tools like Sybil in the early detection of lung cancer and other lung-related diseases.
This work is made possible thanks to the support of AstraZeneca.
Research Literature
2025
2023
Based on 38,922 LDCT images and 2,010 confirmed lung cancers…the AUC for Sybil was 0.93 for lung cancer diagnosed within 1 year, down to 0.79 within 6 years.Journal of Thoracic Oncology
VOLUME 19, ISSUE10 / OCTOBER 2024
